NORWORD, MA — (Marketwired) — 03/30/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced positive topline data from its Phase 2 study evaluating multiple doses of anabasum (fka JBT-101 or Resunab) …
Tag Archives: pulmonary diseases
March, 2017
-
27 March
Genetics Reveal Mysteries of Hard-to-Treat Bacterial Infection in Cystic Fibrosis
New UBC research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore. “Someone with cystic fibrosis has about one less teaspoon of water in the mucous in …
December, 2016
-
21 December
Galapagos Reports Positive Results From Its Phase 2 Study of Its Cystic Fibrosis Drug
Mechelen, Belgium; 20 December 2016 – Galapagos NV (Euronext & NASDAQ: GLPG) reports topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837. The SAPHIRA 1 trial included 26 patients with the G551D mutation in CFTR each receiving three sequential doses of GLPG1837. Of …
October, 2016
-
5 October
AstraZeneca Licenses Pulmonary Drug to Insmed in $150 Million+ Deal
BRIDGEWATER, N.J., Oct. 05, 2016 (GLOBE NEWSWIRE) — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced a licensing agreement with AstraZeneca (NYSE:AZN) for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I (DPP1, also known …
August, 2016
-
17 August
Vertex to Stop of Experimental Cystic Fibrosis Phase 3 Combo Trial
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies that together are expected to enroll more than 1,000 people with cystic fibrosis (CF). Based on a planned interim futility …
June, 2015
-
8 June
Vertex and Parion Sciences Sign Up to $1.17 Billion Cystic Fibrosis Deal
Vertex Pharmaceuticals and Parion Sciences have teamed up to develop new drugs for treatment of cystic fibrosis (CF) and other pulmonary diseases. The companies have initiated a collaboration worth up to $1.17 billion, under which Vertex and Parion will work together to develop investigational epithelial sodium channel (ENaC) inhibitors for …
May, 2015
-
29 May
Pfizer’s Rapamune Receives FDA Approval for Treatment of Rare Lung Disease
Today, Pfizer Inc. announced that US health regulators approved the first drug to treat a rare, progressive lung disease. The company said that the US Food and Drug Administration (FDA) approved its Rapamune (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and …
-
8 May
FDA Staff Questions Benefit of Vertex’s Combo Cystic Fibrosis Drug
US health regulators released briefing documents Friday morning questioning the benefit of Vertex Pharmaceuticals’ combination therapy for cystic fibrosis patients. Ahead of an advisory panel review, scheduled for Tuesday, May 12, US Food and Drug Administration (FDA) staff reviewers questioned one of the two drugs in the combination cystic fibrosis …
March, 2015
-
17 March
Respiratory Biotech Pulmatrix to Merge with Ruthigen
Respiratory biotech Pulmatrix announced an agreement to merge with publicly traded, biopharmaceutical company Ruthigen. The companies have entered into a definitive merger agreement, under which Pulmatrix will become a wholly-owned subsidiary of Ruthigen – which would take the Pulmatrix name and continue Pulmatrix’s work of advancing a new generation of …